Johnson & Johnson

Most Recent

  • Johnson & Johnson office building in Madrid, Spain
    News

    Johnson & Johnson Will Split Its Company in Two, Segment Liabilities

    By Rachel Curry
  • Johnson & Johnson baby talcum powder
    Healthcare

    Will Johnson & Johnson Settle Remaining Talcum Powder Cases?

    By Rachel Curry
  • Johnson & Johnson vaccine
    News

    When Will the Johnson & Johnson COVID-19 Booster Be Available?

    By Rachel Curry
  • Boxes of J&J COVID-19 vaccine
    News

    Johnson & Johnson Booster Shots Could Be Available Soon

    By Danielle Letenyei
  • Johnson & Johnson COVID-19 vaccine
    News

    Will There Be a Johnson & Johnson (JNJ) Booster Shot for COVID-19?

    By Kathryn Underwood
  • Person getting a vaccine
    Healthcare

    Johnson & Johnson Vaccine Paused, Link to Rare Blood Clotting Disorder

    By Danielle Letenyei
  • Nurse preparing Johnson & Johnson vaccine
    News

    Major Johnson & Johnson COVID-19 Vaccine Blunder, Explained

    By Rachel Curry
  • Johnson & Johnson Jannsen COVID-19 vaccine
    Healthcare

    COVID-19 Vaccine Maker Johnson & Johnson Has a Long History

    By Dan Clarendon
  • is janssen pharmaceuticals publicly traded
    Healthcare

    Investing in Janssen Pharmaceuticals Amid COVID-19 Vaccine Push

    By Anuradha Garg
  • when will johnson and johnson vaccine be ready
    Healthcare

    When Will the Johnson & Johnson COVID-19 Vaccine Be Ready?

    By Ambrish Shah
  • uploads///Chart
    Earnings Report

    Major Developments for Johnson & Johnson in 3Q16

    Major developments As discussed previously in this series, Johnson & Johnson’s (JNJ) 3Q16 performance was positive across all of its segments. However, the Consumer segment reported a decline in revenue, as the negative impact of foreign exchange more than offset operational growth. There were several major developments for JNJ during 3Q16. Pharmaceuticals segment In 3Q16, the […]

    By Mike Benson
  • uploads///Pharma
    Earnings Report

    Johnson & Johnson’s Pharmaceuticals Segment Grows in 2Q15

    Johnson & Johnson’s (JNJ) Pharmaceuticals segment grew by 1.0% at constant exchange rates, reporting a revenue of $7,946 million for 2Q15 over 2Q14.

    By Mike Benson
  • uploads///Analysts Reco
    Company & Industry Overviews

    Analysts’ Recommendations for Bristol-Myers Squibb in August 2017

    Of the 23 analysts covering Bristol-Myers Squibb (BMY) in August 2017, six analysts recommended a “strong buy,” and four analysts recommended a “buy.” Ten analysts recommended a “hold,” and three analysts recommended a “sell.”

    By Daniel Collins
  • uploads///Cosentyx
    Company & Industry Overviews

    How Is Novartis’s Cosentyx Positioned after 4Q17?

    In 4Q17, Novartis’s (NVS) Cosentyx generated revenues of $615 million compared to $391 million in 4Q16, which reflected ~57% growth on a year-over-year (or YoY) basis and ~11% growth quarter-over-quarter.

    By Daniel Collins
  • uploads///thermometer _
    Company & Industry Overviews

    Wall Street Analysts Are Mostly Positive on Merck in September

    Of the 19 analysts tracking Merck (MRK) stock in September, four recommended a “strong buy” while ten analysts recommended a “buy.”

    By Daniel Collins
  • uploads///consumer health market
    Company & Industry Overviews

    Could Pfizer and P&G agree on a Consumer Health Business Deal?

    Pfizer (PFE) has been looking to sell its consumer health business since October 2017.

    By Sarah Collins
  • uploads///Chart
    Company & Industry Overviews

    What Analysts Recommend for Novartis in March 2018

    As discussed earlier, Novartis (NVS) reported EPS (earnings per share) of $1.21 on revenues of $12.9 billion during 4Q17.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    A Look at Johnson & Johnson’s Post-2Q17 Valuation

    Headquartered in New Jersey, Johnson & Johnson (JNJ) is one of the largest pharmaceutical companies, with its products sold in over 200 countries worldwide. This series will look at how it has performed since its 2Q17 earnings announcement.

    By Mike Benson
  • uploads///Article
    Company & Industry Overviews

    Lilly’s Total Returns Are Lower than Some Pharma ETFs

    The total return for Lilly’s share price on the NYSE from July 2010 to June 2015 has been around 17.9%. This is lower than a few of the pharmaceutical ETFs.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Johnson & Johnson’s Valuation Cheat Sheet

    On January 26, 2017, the company was trading at a forward PE of ~15.8x. Based on the last five years’ multiple range, JNJ’s current valuation is neither high nor low.

    By Mike Benson
  • uploads///Article
    Company & Industry Overviews

    Sanofi Increased Net Revenues in 2014

    Sanofi’s net revenues increased by ~2.5% to 33.8 billion euros in 2014, as compared to $23.2 billion in 2013.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    Celgene’s Revlimid Expected to Post Strong Revenue in 2017

    According to unaudited financial results published by Celgene (CELG) on January 9, 2017, Revlimid sales for 2016 are about $7.0 billion, a YoY rise of about 20.0%.

    By Margaret Patrick
  • uploads///Article
    Earnings Report

    Novartis’s Adjusted Earnings per Share Declined 7% in 2Q15

    Novartis (NVS) posted its 2Q15 earnings on July 21, 2015. The company achieved adjusted EPS of $1.27 for 2Q15, ~7% lower than in 2Q14.

    By Mike Benson
  • uploads///Graph
    Earnings Report

    How Gilead Sciences’ Gross Margin Outshines Its Peers

    Despite a year-over-year (or YoY) drop in revenues in 2Q16, Gilead Sciences (GILD) managed to earn gross margins of about 92%.

    By Margaret Patrick
  • uploads///
    Company & Industry Overviews

    Facebook: There Remains a Need for Revenue Diversification

    According to eMarketer, Facebook (FB) took 19.9% of total US digital advertising funds in 2017, and Google (GOOGL) took 38.6%.

    By Neha Gupta
  • uploads///
    Company & Industry Overviews

    Why a Google Exec Interviewed Ex-Terrorists

    Google, Facebook (FB), Twitter (TWTR), and Snap (SNAP) might be losing sleep because authorities are pointing fingers at them for allowing their platforms to breed extremist ideologies.

    By Ruchi Gupta
  • uploads///Pfizer revenues
    Company & Industry Overviews

    How Did Pfizer Perform in 3Q17?

    In 3Q17, Pfizer (PFE) generated revenues of $13.2 billion, an increase of ~1% on a year-over-year (or YoY) basis and a 1% increase on a quarter-over-quarter basis.

    By Daniel Collins
  • uploads///Chart
    Earnings Report

    Analysts’ Recommendations for Merck & Co. after 4Q17

    Merck & Co. (MRK) missed Wall Street analysts’ estimates for revenues but surpassed analysts’ estimates earnings per share.

    By Mike Benson
  • uploads///TSRO
    Company & Industry Overviews

    Gauging Analysts’ Views on Tesaro Stock

    In November, of the total 21 analysts covering Tesaro (TSRO) stock, 13 have given it “buy” or higher ratings, and eight have given it “hold” ratings.

    By Kenneth Smith
  • uploads///Chart
    Earnings Report

    What Does Johnson & Johnson Predict for Its Medical Devices Segment?

    Johnson & Johnson’s (JNJ) medical devices segment deals with vision care, cardiovascular care, specialty surgery, orthopedics, surgical care, and diabetes care.

    By Mike Benson
  • uploads///Part  Graph
    Company & Industry Overviews

    Inside XLV’s Large Caps: Pfizer’s 1Q16 Earnings

    Pfizer recently rose by 2.7% on revenues of $13 billion for 1Q16, as compared to $10.9 billion in 1Q15, which represents a growth of 20% YoY.

    By Peter Neil
  • uploads///Chart
    Company & Industry Overviews

    Merck’s Valuation Cheat Sheet for Fiscal 1Q16

    Merck & Co.’s (MRK) current valuation is neither high nor low. Its valuation multiple has followed the industry’s overall trend over the last five years.

    By Mike Benson
  • uploads///revenue estimates
    Earnings Report

    Will Medtronic Maintain Its Revenue Growth Momentum in Fiscal 1Q18?

    In fiscal 1Q18, Wall Street analysts expect Medtronic’s (MDT) revenue to be ~$7.45 billion, which represents a rise of ~4% in comparison to its fiscal 1Q17 revenue of $7.17 billion.

    By Sarah Collins
  • uploads///close up _
    Earnings Report

    Pfizer Missed Analysts’ Third-Quarter Revenue Estimates

    Pfizer (PFE) released its third-quarter earnings on October 30.

    By Mike Benson
  • uploads///Costs
    Earnings Report

    Bristol-Myers Squibb’s Profitability and Financial Guidance

    Bristol-Myers Squibb estimates that its revenues will be between $15.5 billion and $15.9 billion, which is nearly flat as compared to 2014 revenues of $15.9 billion.

    By Mike Benson
  • uploads///REVENUE ESTIMATES
    Earnings Report

    Analysts Expect Medtronic’s Revenue to Rise 4% in Fiscal 4Q17

    Wall Street analysts expect Medtronic’s (MDT) revenue to be ~$7.9 billion in fiscal 4Q17, a rise of ~4% compared to its fiscal 4Q16 revenue of $7.6 billion.

    By Sarah Collins
  • uploads///
    Company & Industry Overviews

    Apple Watch Business Will Be Interesting to Watch in 2018

    Apple (AAPL) and its partner AliveCor scored an important milestone in the final weeks of 2017 in their push into the multibillion-dollar digital health market.

    By Ruchi Gupta
  • uploads///Graph
    Earnings Report

    Venclexta Witnessed Healthy Demand Trends in 1Q17

    AbbVie’s (ABBV) Venclexta was approved by the FDA on April 11, 2016. AbbVie has also successfully launched Venclexta in Germany and France.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Valeant’s Dermatology Business Felt Pricing Pressure in 2016

    Dermatology pricing trends Valeant Pharmaceuticals’ (VRX) dermatology business witnessed intense pricing pressure in 2016, due to a change in the company’s distribution model in 4Q15. While Valeant previously marketed its dermatology drugs through specialty pharmacies, the company now distributes its products through Walgreens. To learn about the company’s current distribution model, please refer to How Valeant Plans […]

    By Margaret Patrick
  • uploads///the device _
    Company & Industry Overviews

    JNJ’s Medical Devices Growth Plans amid Changing Market Dynamics

    Johnson & Johnson (JNJ) has been working on changing its business model.

    By Sarah Collins
  • uploads///ORAL CARE
    Company & Industry Overviews

    Johnson & Johnson Is Reinventing Its Oral Care Franchise

    Johnson & Johnson’s (JNJ) oral care business registered an operational sales decline of 3.2% in fiscal 2017.

    By Sarah Collins
  • uploads///Tracking error in the VNQ ETF tracking the RMZ Index
    Healthcare

    Comparing ETNs with ETFs: The must-know pros of ETNs

    ETNs are free of tracking errors, and investors can defer taxation until they mature or are sold.

    By Surbhi Jain
  • uploads///Graph
    Company & Industry Overviews

    Siliq May be a Strong Growth Driver for Valeant in 2017

    Siliq growth trends On February 15, 2017, the FDA approved injectable biologic therapy Siliq (brodalumab) as a treatment option for moderate-to-severe plaque psoriasis patients. Siliq is for psoriasis patients eligible for systemic therapy or phototherapy, and are not responding sufficiently or have stopped responding to these treatment options. To learn more about Siliq, please refer to What Are […]

    By Margaret Patrick
  • uploads///revenue estimates
    Earnings Report

    Medtronic’s Revenue Is Estimated to Rise in Fiscal 2Q17

    On November 22, 2016, Medtronic (MDT) will announce its fiscal 2Q17 earnings for the period that ended on October 31, 2016.

    By Sarah Collins
  • uploads///Graph
    Company & Industry Overviews

    International Segment: Key Driver of VRX’s Revenue Growth in 2016

    In the first nine months of 2016, the Bausch + Lomb/International segment reported revenues of ~$3.4 billion, which equals year-over-year (or YoY) growth of ~0.4%.

    By Margaret Patrick
  • uploads///animas exit from insulin pump business
    Company & Industry Overviews

    Tandem Diabetes Care’s International Expansion Strategy

    Tandem Diabetes Care (TNDM) is slated to begin its international expansion later this year to capture opportunities arising after Johnson & Johnson’s (JNJ) exit from the insulin pump market, which was announced in October 2017.

    By Sarah Collins
  • uploads///Growth
    Earnings Report

    Johnson & Johnson’s 3Q15 Changes in Growth Rate

    Foreign exchange rates seem to have had a negative impact on Johnson & Johnson’s growth rate since ~50% of total revenues are reported from sales outside the US.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    Emerging Markets Drive Abbott’s Nutritional Business Growth

    In 1Q17, Abbott Laboratories’ (ABT) Nutritional segment reported revenue of nearly $1.6 billion, a year-over-year (or YoY) fall of ~1%.

    By Margaret Patrick
  • uploads///Chart
    Earnings Report

    What to Expect from Pfizer’s 2Q16 Earnings

    In Pfizer’s 2Q16 results, analysts expect to see EPS (or earnings-per-share) of $0.62 and revenues of ~$13.0 billion for 2Q16. The company has surpassed Wall Street analysts’ estimates for EPS over the last few quarters.

    By Mike Benson
  • uploads///Graph
    Earnings Report

    Amgen’s Nephrology Drugs Expect Falling Revenue in 4Q15

    Analysts projected a fall in the revenue for Amgen’s nephrology drugs, Aranesp and Epogen, in 4Q15. The drugs are expected to suffer in the coming quarters.

    By Margaret Patrick
  • uploads///minimed g launch dynamics
    Company & Industry Overviews

    Diabetes Management Breakthrough: Medtronic’s MiniMed 670G

    On June 7, 2017, Medtronic (MDT) announced the launch of MiniMed 670G—the world’s first HCL (hybrid closed loop) insulin delivery system.

    By Sarah Collins
  • uploads///pg pm
    Company & Industry Overviews

    Henkel Acquired Procter & Gamble’s Haircare Brands

    Procter & Gamble (PG) has a market cap of $224.1 billion. PG rose by 0.35% to close at $82.84 per share on March 3, 2016.

    By Gabriel Kane
  • uploads///Graph
    Company & Industry Overviews

    Gilead Sciences’ Product Line Extension

    As part of its significant product line extension, Gilead Sciences (GILD) is entering therapeutic areas such as oncology, pulmonology, and cardiology.

    By Margaret Patrick
  • uploads///
    Earnings Report

    Why HP Is Banking on 3D Printing

    In 2016, HP stated that it aims to reinvent the printing experience and has now unveiled the world’s smallest all-in-one inkjet printer.

    By Adam Rogers
  • uploads///aid __
    Company & Industry Overviews

    Boston Scientific Expands Its Endoscopy Business with EMcision Acquisition

    On March 5, 2018, Boston Scientific (BSX) announced the acquisition of EMcision, which will expand the company’s endoscopy business.

    By Sarah Collins
  • uploads///women health
    Company & Industry Overviews

    How Johnson & Johnson Plans to Restore Women’s Health Sales

    Johnson & Johnson (JNJ) reported sales of $3.4 billion in its consumer business in the first quarter, with 7% of it from its women’s health business.

    By Sarah Collins
  • uploads///omnichannel presence
    Company & Industry Overviews

    Johnson & Johnson’s Growth Strategy: Expand Emerging Channels

    Amid the increasing presence of digital technology, Johnson & Johnson (JNJ) has recognized the need to expand its channel presence.

    By Sarah Collins
  • uploads///Emend Temodar Revenues
    Company & Industry Overviews

    How Merck’s Oncology Drugs Emend and Temodar Could Perform in 2017

    In 2016, Merck’s (MRK) Emend reported revenues of around $549 million, which reflected 3% year-over-year growth.

    By Daniel Collins
  • uploads///share price on Oct
    Earnings Report

    ABT Stock Fell ~3.3% on October 10 despite Analyst Upgrade

    On October 10, Abbott Laboratories (ABT) ended the trading day at $68.92, down ~3.3% from the previous day’s close.

    By Sarah Collins
  • uploads///gks coo
    Earnings Report

    Cooper Companies Reported Mixed 2Q15 Results

    Cooper Companies (COO) is a $7.33 billion global medical device company. The company has two business units, CooperVision and CooperSurgical.

    By Gabriel Kane
  • uploads///Chart
    Earnings Report

    How Analysts Rate Bristol-Myers Squibb in 1Q18

    Wall Street analysts estimate Bristol-Myers Squibb’s top line to rise 6.5% to ~$5.2 billion in 1Q18.

    By Mike Benson
  • uploads///PE ratio
    Earnings Report

    Key Factors That Impact Johnson & Johnson’s Forward Valuation

    Two factors expected to impact Johnson & Johnson’s forward valuation are increasing competition for Olysio and further decline in international revenues.

    By Nicole Sario
  • uploads///Chart  GSK
    Company & Industry Overviews

    How GlaxoSmithKline Stock Performed in 1Q18

    GlaxoSmithKline stock has risen ~6.4% in 1Q18, while its stock has risen ~12.6% YTD (year-to-date) as of April 6, 2018.

    By Mike Benson
  • uploads///pina messina  unsplash
    Company & Industry Overviews

    Eli Lilly’s Valuation on May 17

    On May 17, Eli Lilly was trading at a forward PE multiple of 15.2x, which compares to the industry average of 13.6x.

    By Mike Benson
  • uploads///
    Earnings Report

    Can HP Increase Its Penetration in the 3D Printing Segment?

    HP, a market leader in the traditional printing business for the past 30 years, is now eyeing the lucrative and high-growth 3D Printing market.

    By Adam Rogers
  • uploads///pharma
    Earnings Report

    Oncology Portfolio Sales Drove J&J’s Pharmaceuticals Business

    Johnson & Johnson (JNJ) reported Pharmaceuticals segment sales of $10.4 billion in Q2 2018 during its earnings release on July 17.

    By Sarah Collins
  • uploads///Chart
    Earnings Report

    Analyzing Johnson & Johnson’s 1Q18 Profitability

    Johnson & Johnson (JNJ) reported revenues of $20.0 billion during 1Q18, 12.6% growth as compared to revenues of $17.8 billion during 1Q17.

    By Mike Benson
  • uploads///cancer _
    Company & Industry Overviews

    Tesaro Stock Up over 16% on Rumors of Acquisition by Roche

    Yesterday, Tesaro (TSRO) stock rose ~16.3%, triggered by rumours of an acquisition bid by Roche (RHHBY), which registered a stock price rise of ~2.1%.

    By Sarah Collins
  • uploads///DIABETES
    Company & Industry Overviews

    Johnson & Johnson Gets FDA Approval for Type 2 Diabetes Drug

    On September 21, 2016, the FDA approved Jannsen Pharmaceuticals’ Invokamet XR for the treatment of adults suffering from Type 2 diabetes.

    By Sarah Collins
  • Energy & Utilities

    Why investors prefer dividends in a low interest rate environment

    The Fed’s policy of keeping the nominal interest rates at a zero lower bound leads some investors to seek higher and stabler income elsewhere. The low-interest rate regime may force risk-taking investors towards the higher-cost debt of high yield bonds.

    By Surbhi Jain
  • uploads///Chart
    Company & Industry Overviews

    How Did Bristol-Myers Squibb’s Other Segments Perform in 3Q16?

    Bristol-Myers Squibb’s (BMY) neuroscience segment sales fell over 37% in 3Q16, while the immunoscience segment sales rose ~18% in 3Q16 as compared to 3Q15.

    By Mike Benson
  • uploads///Revlimid revenue
    Company & Industry Overviews

    Revlimid Could Continue to Drive Celgene’s Revenue Growth in 2017

    In 2016, Celgene’s (CELG) Revlimid generated revenues of around $6.9 billion, which reflected a ~20% year-over-year (or YOY) growth.

    By Daniel Collins
  • uploads///Opioid
    Cannabis

    Opioid Crisis: Is Cannabis Legalization a Good Idea?

    According to the CDC, about 400,000 people died from opioid overdoses from 1999 to 2017. The number includes deaths from prescription and illegal opioids.

    By Sirisha Bhogaraju
  • uploads///Humira Revenues
    Company & Industry Overviews

    Humira May Continue to Drive AbbVie’s Revenue Growth

    In 2016, AbbVie’s (ABBV) drug Humira reported revenue of ~$16.0 billion, which reflected a ~15% year-over-year (or YoY) rise.

    By Daniel Collins
  • uploads///becdaabdacaceddd
    Earnings Report

    Johnson & Johnson Stock Remained Neutral to 2Q15 Earnings

    Due to the decelerating revenue growth over all segments, Johnson & Johnson (JNJ) reported a decrease in its top line by ~8.8% in its 2Q15 earnings release on July 14, 2015.

    By Mike Benson
  • uploads///Chart  Other
    Earnings Report

    A Look at Bristol-Myers Squibb’s Other Segments in 1Q17

    Bristol-Myers Squibb’s (BMY) other segments include the Neuroscience segment, the Cardiovascular segment, and the Immuno-Science segment.

    By Mike Benson
  • uploads///genvoya
    Company & Industry Overviews

    How Could TAF-Based Regimen Drive Gilead Sciences’s Growth?

    Gilead Sciences’s (GILD) TAF-based (tenofovir alafenamide) regimen comprises three products: Genvoya, Descovy, and Odefsey.

    By Jillian Dabney
  • uploads///Chart
    Company & Industry Overviews

    Pfizer’s Growth Rate and Estimates

    Pfizer (PFE) reported an EPS of $0.74 on revenues of ~$13.5 billion during the second quarter, which beat analysts’ estimate of ~$13.3 billion.

    By Mike Benson
  • uploads///Diabetes
    Company & Industry Overviews

    Januvia and Janument: An Update on Merck’s Diabetes Franchise after 2Q17

    In 2Q17, Merck’s (MRK) Januvia generated revenues of around $948 million, which reflected an ~11% decline on a year-over-year basis and 13% growth on a quarter-over-quarter basis.

    By Daniel Collins
  • uploads///erleada
    Company & Industry Overviews

    Johnson & Johnson’s Erleada Approved by Health Canada

    On July 4, Johnson & Johnson’s (JNJ) pharmaceuticals division, Janssen, received Health Canada’s approval for its drug Erleada.

    By Sarah Collins
  • uploads///syringe _
    Company & Industry Overviews

    Johnson & Johnson in the Changing Consumer Market Landscape

    Although changing consumer market dynamics pose challenges for Johnson & Johnson (JNJ), it’s confident it will be able to adapt.

    By Sarah Collins
  • uploads///pipeline
    Company & Industry Overviews

    Pfizer Has Strong Track Record since 2010

    As of November 1, Pfizer had ~94 projects in various development stages. More than 40% of these projects are in phase three or the registration phase.

    By Jillian Dabney
  • uploads///
    Macroeconomic Analysis

    Commodities are Battered among the Asset Classes

    Commodities generally have a positive correlation with inflation. They are considered to be an attractive investment option from a diversification point of view.

    By Vineet Kulkarni
  • uploads///Graph
    Earnings Report

    Behind Celgene’s Blockbuster Revenue Hit in 4Q16

    In 2016, Celgene’s (CELG) Otezla attained blockbuster status by earning revenues in excess of $1 billion as a therapy for psoriasis and psoriatic arthritis.

    By Margaret Patrick
  • uploads///Chart
    Earnings Report

    What to Expect from Johnson & Johnson’s 4Q15 Earnings

    Johnson & Johnson has returned nearly 1.2% year-to-date while Sanofi, Merck, and Novartis have returned ~0.5%, -4.4%, and -3.5%, respectively.

    By Mike Benson
  • uploads///Oncology
    Earnings Report

    AstraZeneca’s Oncology Segment: How Did It Perform in 2Q15?

    AstraZeneca’s oncology segment is another key focus area. The segment contributed 11.6% in 2014 and 12.1% in 2Q15. Key products for oncology are Zoladex and Faslodex.

    By Mike Benson
  • uploads///innovation strategies
    Company & Industry Overviews

    How Johnson & Johnson’s Partnerships Enhance Customer Value

    Johnson & Johnson’s key innovation strategies include creating value through strategic customer partnerships and solutions.

    By Sarah Collins
  • uploads///darzalex
    Company & Industry Overviews

    Johnson & Johnson Seeks EU and US Label Expansion for Darzalex

    Johnson & Johnson’s (JNJ) subsidiary Janssen Pharmaceuticals filed regulatory submissions for label expansion of its multiple myeloma drug Darzalex.

    By Sarah Collins
  • uploads///Chart
    Earnings Report

    Analyzing Johnson & Johnson’s Segment-Wise Performance in 1Q18

    Johnson & Johnson reported growth across all three of its segments: the pharmaceutical segment, the consumer health segment, and the medical devices segment.

    By Mike Benson
  • uploads///flexibility and responsiveness
    Company & Industry Overviews

    Johnson & Johnson Responds to Meet Consumer Needs Faster

    Johnson & Johnson is committed to driving its margins through optimization of costs and improving efficiency and productivity.

    By Sarah Collins
  • uploads///pills _
    Earnings Report

    Johnson & Johnson Reports Strong Second-Quarter Results

    Johnson & Johnson (JNJ) reported its second-quarter earnings results before the market opened on July 17. The company reported sales of $20.8 billion.

    By Sarah Collins
  • uploads///JJ partnerships
    Company & Industry Overviews

    JNJ’s Latest Acquisition Aims to Broaden Its Orthopedics Business

    On May 14, one of JNJ’s subsidiaries, DePuy Synthes, announced its acquisition of the assets of Medical Enterprises Distribution.

    By Sarah Collins
  • uploads///beauty
    Company & Industry Overviews

    How Johnson & Johnson Is Driving Growth for Beauty Products

    In its fiscal first quarter, Johnson & Johnson (JNJ) reported sales of $1.1 billion for its beauty franchise.

    By Sarah Collins
  • uploads///patents
    Company & Industry Overviews

    Why Is Enbrel So Important for Amgen?

    YTD, Amgen’s (AMGN) stock has already fallen 9%. Perhaps the pressure that Enbrel (etanercept) is seeing is to blame for the negative investor sentiment.

    By Jillian Dabney
  • uploads///Chart
    Macroeconomic Analysis

    Upbeat Earnings from Johnson & Johnson and 3M Boosted SPY

    3M stock (MMM) jumped 5.2% after the company’s quarterly report beat analysts’ estimates.

    By Renee Blakely
  • uploads///dna _
    Company & Industry Overviews

    Merck’s Relebactam Met Primary Endpoints in Phase 3 Study

    Merck’s Relebactam is an investigational drug for the treatment of certain forms of imipenem-non-susceptible bacterial infections.

    By Mike Benson
  • uploads///virus _
    Earnings Report

    Bristol-Myers Squibb’s 1Q18 Earnings Beat Wall Street Estimates

    Bristol-Myers Squibb beat Wall Street analysts’ estimates for earnings per share and revenues in 1Q18.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    How Could JNJ’s Pharmaceuticals Business Perform in Q3 2018?

    Tremfya reported sales of $126 million in the second quarter, compared to $72 million in sales reported in the first quarter.

    By Sarah Collins
  • uploads///CUSTOMER SPECIFIC COMMERCIAL MODELS
    Company & Industry Overviews

    How JNJ Is Recreating Its Commercial Model for Medical Devices

    JNJ has been working on innovating its business model to be able to provide therapies and solutions to its customers according to their changing needs.

    By Sarah Collins
  • uploads///Chart
    Macroeconomic Analysis

    Analyzing the iShares’ Quality Smart Beta ETFs

    The iShares MSCI International Developed Quality Factor ETF (IQLT) is a similar fund to QUAL with respect its strategy for selecting stock.

    By Ivan Kading
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.